Target intelligence / Profile preview

Baculoviral IAP repeat-containing protein 5 messenger RNA 3' untranslated region (BIRC5 mRNA 3'UTR)

Target
BIRC5 mRNA 3'UTR
Molecular classification
Messenger RNA, Untranslated region, Inhibitor of apoptosis protein (IAP) family
01

Overview

The BIRC5 mRNA 3'UTR is the 3' untranslated region of the transcript encoding Survivin, a member of the inhibitor of apoptosis (IAP) protein family. This region serves as a critical regulatory hub, containing multiple binding sites for microRNAs (miRNAs) and RNA-binding proteins that dictate mRNA stability and translational efficiency (NCBI Gene ID: 332). Survivin is uniquely characterized by its dual role in inhibiting apoptosis and facilitating cell division, making it indispensable for tumor cell survival and proliferation. While Survivin is highly expressed in nearly all human cancers, its expression is minimal in most normal adult tissues, which makes its mRNA a highly specific therapeutic target (UniProt: O15392). Drugs targeting the BIRC5 mRNA 3'UTR, including antisense oligonucleotides and miRNA mimics, aim to downregulate Survivin protein levels to trigger apoptosis and sensitize tumors to conventional therapies. Clinical and preclinical studies have explored these RNA-targeting strategies to overcome the 'undruggable' nature of the Survivin protein itself (PubMed: 21464304, 19808977).

Other names
Survivin mRNA 3'UTRAPI4 mRNA 3'UTRIAP4 mRNA 3'UTRBIRC5 3'-untranslated region
02

Mechanism of action

Antisense oligonucleotides and RNA interference (RNAi) molecules bind to the 3'UTR to induce RNase H-mediated degradation of the mRNA or to block translation by preventing the assembly of the translation initiation complex, thereby reducing the levels of the Survivin protein.

03

Biological functions

Regulation of mRNA stabilityRegulation of translationApoptosis inhibitionCell cycle regulationMitosis
04

Disease associations

CancerSolid tumorHematologic malignancy
05

Safety considerations

Off-target effects of RNA-based therapeuticsPotential toxicity in proliferating normal cells such as hematopoietic stem cellsSystemic delivery challenges and immune activation by oligonucleotides
06

Interacting drugs

LY2181308

4 more in the full profile.

07

Biomarkers

Survivin mRNA expression levelsSurvivin protein expression (IHC)BIRC5 gene amplification

Beyond the preview

Go deeper on Baculoviral IAP repeat-containing protein 5 messenger RNA 3' untranslated region (BIRC5 mRNA 3'UTR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Baculoviral IAP repeat-containing protein 5 messenger RNA 3' untranslated region (BIRC5 mRNA 3'UTR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call